Payment overview · 2025
General Payments
$2,224.16
48 reported records · 23 companies
Healthcare provider profile · identity verified
Christopher S Hiler, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PHOENIX, AZ · NPI 1336133701
Verified facts
What the public records show
CMS Open Payments records show Christopher S Hiler, M.D. received $2,224.16 in general payments during 2025 across 48 reported records.
Boston Scientific Corporation accounted for 56.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,253.80 | 56.4% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $140.30 | 6.3% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $137.77 | 6.2% | 6 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $117.91 | 5.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $53.01 | 2.4% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $48.79 | 2.2% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.64 | 2.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.24 | 2.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $44.48 | 2.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.92 | 2.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $36.72 | 1.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.06 | 1.6% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $26.53 | 1.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $26.22 | 1.2% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $22.42 | 1.0% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $22.32 | 1.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.49 | 1.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.93 | 0.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.00 | 0.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.07 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.67 | 0.7% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $14.35 | 0.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.52 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,507.61 | 46 |
| Travel and Lodging | $716.55 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $1,089.89 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $140.30 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $137.77 | 6 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $129.59 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $117.91 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $94.61 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $94.61 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $48.79 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.64 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $44.48 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $44.48 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.92 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $36.72 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $36.44 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.06 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.06 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.06 | 2 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $34.32 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.64 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.64 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $26.53 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $26.22 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| OCTRODE Normalized: octrode |
Device | Abbott Laboratories | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 183 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 178 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 88 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
88 | 20 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
30 | 22 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
183 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
178 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1083 | 365 |
| Metformin Hcl | Metformin Hcl | 733 | 239 |
| Alendronate Sodium | Alendronate Sodium | 692 | 230 |
| Levothyroxine Sodium | Levothyroxine Sodium | 681 | 193 |
| Lisinopril | Lisinopril | 586 | 196 |
| Diclofenac Sodium | Diclofenac Sodium | 540 | 173 |
| Losartan Potassium | Losartan Potassium | 406 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 403 | 123 |
| Pioglitazone Hcl | Pioglitazone Hcl | 403 | 136 |
| Gabapentin | Gabapentin | 308 | 113 |
| Tamsulosin Hcl | Tamsulosin Hcl | 292 | 107 |
| Omeprazole | Omeprazole | 273 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 244 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 237 | 74 |
| Oxycodone Hcl | Oxycodone Hcl | 237 | 40 |
| Finasteride | Finasteride | 203 | 75 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 188 | 82 |
| Carvedilol | Carvedilol | 185 | 60 |
| Farxiga | Dapagliflozin Propanediol | 183 | 62 |
| Jardiance | Empagliflozin | 178 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 33 |
| Ezetimibe | Ezetimibe | 170 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 162 | 22 |
| Januvia | Sitagliptin Phosphate | 160 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 60 |
| Potassium Chloride | Potassium Chloride | 152 | 54 |
| Alprazolam | Alprazolam | 144 | 26 |
| Trazodone Hcl | Trazodone Hcl | 143 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 55 |
| Famotidine | Famotidine | 139 | 54 |
| Azithromycin | Azithromycin | 135 | 110 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 125 | 52 |
| Furosemide | Furosemide | 122 | 53 |
| Ibuprofen | Ibuprofen | 121 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 36 |
| Simvastatin | Simvastatin | 120 | 42 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 108 | 39 |
| Allopurinol | Allopurinol | 95 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 26 |
| Linzess | Linaclotide | 88 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 36 |
| Ozempic | Semaglutide | 86 | 26 |
| Glipizide | Glipizide | 81 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 30 |
| Naproxen | Naproxen | 77 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 22 |
| Sertraline Hcl | Sertraline Hcl | 66 | 19 |
| Bupropion Xl | Bupropion Hcl | 64 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 51 |
| Atenolol | Atenolol | 63 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 18 |
| Montelukast Sodium | Montelukast Sodium | 60 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 25 |
| Ketoconazole | Ketoconazole | 59 | 16 |
| Meclizine Hcl | Meclizine Hcl | 55 | 33 |
| Ondansetron Odt | Ondansetron | 54 | 21 |
| Trulicity | Dulaglutide | 53 | 12 |
| Glipizide Er | Glipizide | 51 | 18 |
| Clotrimazole | Clotrimazole | 50 | 17 |
| Eliquis | Apixaban | 50 | 22 |
| Methylprednisolone | Methylprednisolone | 50 | 46 |
| Lovastatin | Lovastatin | 49 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | 18 |
| Myrbetriq | Mirabegron | 43 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 41 | suppressed |
| Diazepam | Diazepam | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | 11 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 27 |
| Acyclovir | Acyclovir | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 13 |
| Prolia | Denosumab | 30 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 22 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | 11 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Tradjenta | Linagliptin | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 23 |
| Baclofen | Baclofen | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Metronidazole | Metronidazole | 15 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | 11 |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,224.16 · 48 records | Boston Scientific Corporation | ABRYSVO, ACCRUFER, AIRSUPRA, APTIMA, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, General - Therapies, INSPIRE, JARDIANCE, Kerendia, Korlym, LINZESS, LifeVest, MOUNJARO, OCTRODE, OTEZLA, Ozempic, PREVNAR 20, REPATHA, ROTATEQ, Rybelsus, Senza, VAXNEUVANCE, Veozah, WATCHMAN, WATCHMAN FLX, XIFAXAN, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error